company background image
BDSX logo

Biodesix NasdaqGM:BDSX Stock Report

Last Price

US$1.57

Market Cap

US$228.4m

7D

17.2%

1Y

-9.2%

Updated

22 Dec, 2024

Data

Company Financials +

My Notes

Capture your thoughts, links and company narrative

Biodesix, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Biodesix
Historical stock prices
Current Share PriceUS$1.57
52 Week HighUS$2.21
52 Week LowUS$1.11
Beta1.14
1 Month Change22.66%
3 Month Change-1.26%
1 Year Change-9.25%
3 Year Change-65.87%
5 Year Changen/a
Change since IPO-87.74%

Recent News & Updates

With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Nov 21
With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Sep 24
Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Recent updates

With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Nov 21
With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Sep 24
Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

Jun 12
Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Mar 03
With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Jan 04
Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

Jul 16
It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

A Second Look At Biodesix

Oct 18

Biodesix expects Q3 revenue above the consensus

Oct 11

Biodesix GAAP EPS of -$0.40 beats by $0.07, revenue of $10.95M beats by $2.12M

Aug 04

Biodesix: Bad Diagnosis

May 26

Analysts' Revenue Estimates For Biodesix, Inc. (NASDAQ:BDSX) Are Surging Higher

Mar 15
Analysts' Revenue Estimates For Biodesix, Inc. (NASDAQ:BDSX) Are Surging Higher

Shareholder Returns

BDSXUS HealthcareUS Market
7D17.2%-4.1%-2.4%
1Y-9.2%-10.2%23.4%

Return vs Industry: BDSX matched the US Healthcare industry which returned -10.2% over the past year.

Return vs Market: BDSX underperformed the US Market which returned 23.3% over the past year.

Price Volatility

Is BDSX's price volatile compared to industry and market?
BDSX volatility
BDSX Average Weekly Movement10.8%
Healthcare Industry Average Movement7.6%
Market Average Movement6.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: BDSX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: BDSX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2005217Scott Huttonwww.biodesix.com

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to establish the patient’s prognosis and help guide treatment decisions.

Biodesix, Inc. Fundamentals Summary

How do Biodesix's earnings and revenue compare to its market cap?
BDSX fundamental statistics
Market capUS$228.38m
Earnings (TTM)-US$43.82m
Revenue (TTM)US$65.56m

3.5x

P/S Ratio

-5.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BDSX income statement (TTM)
RevenueUS$65.56m
Cost of RevenueUS$14.61m
Gross ProfitUS$50.96m
Other ExpensesUS$94.78m
Earnings-US$43.82m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.30
Gross Margin77.72%
Net Profit Margin-66.84%
Debt/Equity Ratio129.7%

How did BDSX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 08:37
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biodesix, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sung Ji NamBTIG
Kyle MiksonCanaccord Genuity
William BonelloCraig-Hallum Capital Group LLC